Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr Jain on Existing Challenges Within the TNBC Treatment Paradigm

March 3rd 2025

Angela Jain, MD, details ongoing challenges with identifying optimal treatments for patients with triple-negative breast cancer.

TNBC Awareness Day Emphasizes Progress in Treatment Strategies

March 3rd 2025

Angela Jain, MD, discussed the current treatment paradigm in triple-negative breast cancer (TNBC), including currently investigated therapies, during TNBC Awareness Day.

The OncFive: Top Oncology Articles for the Week of 2/23

March 1st 2025

Perioperative pembrolizumab sBLA gets priority review in HNSCC, nivolumab/ipilimumab sBLA in MSI-H/dMMR CRC is under review, and more from OncLive this week.

Tips for Tomorrow: What 4 Experts Wish They Knew Earlier About ADCs

February 26th 2025

Clinicians with years of ADC therapy experience provide insights on the drug class and what is most important to keep in mind when treating patients.

First-Line Camizestrant Plus CDK4/6 Inhibition Boosts PFS in ESR1+, HR+/HER2-Negative Advanced Breast Cancer

February 26th 2025

Camizestrant plus a CDK4/6 inhibitor was safe and effective in frontline ESR1-mutated HR-positive/HER2-negative advanced breast cancer.

SABCS Highlights and Future Directions in the Treatment of Breast Cancer

February 26th 2025

Panelists discuss how the continued evolution of HER2-directed therapies, particularly the expanding role of trastuzumab deruxtecan (T-DXd) across different breast cancer settings, has transformed the treatment landscape, while emphasizing the importance of appropriate patient selection, optimal sequencing strategies, and the need for education around early adoption of promising therapies in community practice settings.

Cardio-Oncology Investigations Begin to Uncover More Links Between CVD and Breast Cancer

February 26th 2025

For American Heart Month, cardiologist Amy M. Ahnert, MD, and oncologist Kevin T. Nead, MD, MPhil, unpacked the link between CVD and breast cancer.

Emerging Frontline, Adjuvant, and Neoadjuvant Strategies with T-DXd in HER2+ Breast Cancer

February 26th 2025

Panelists discuss how emerging data from trials such as DESTINY-Breast09, which is evaluating first-line trastuzumab deruxtecan (T-DXd) with or without pertuzumab, could potentially reshape the treatment paradigm for HER2+ metastatic breast cancer (mBC) by establishing new standards for initial therapy and optimal combination approaches.

Dr Fisch on the Incidence of Neutropenia With Sacituzumab Govitecan in Advanced Breast Cancer

February 26th 2025

Samantha Fisch, MD, discusses rates of neutropenia in patients with advanced breast cancer treated with sacituzumab govitecan.

ADCs: Recent Data of Dato-DXd from TROPION-Breast01

February 25th 2025

Panelists discuss the results of the datopotamab deruxtecan (Dato-DXd) TROPION-Breast01 trial and its potential uses in clinical practice.

Clinical Developments of Antibody-Drug Conjugates (ADCs) in HR+/HER2– mBC

February 25th 2025

Panelists discuss the latest antibody-drug conjugate developments for HR+/HER2– metastatic breast cancer (mBC), including sacituzumab govitecan and trastuzumab deruxtecan.

HyperVIEW X-Ray System Receives FDA Breakthrough Device Designation for Breast Cancer Imaging

February 21st 2025

The HyperVIEW X-ray system has received breakthrough device designation from the FDA for contrast-enhanced imaging for diagnosis of breast cancer.

Novel and Emerging Strategies for HER2+ Breast Cancer With Brain Metastases

February 19th 2025

Panelists discuss how sequential therapy selection for patients with HER2+ breast cancer with progressive brain metastases requires careful consideration of prior treatments, patterns of progression, symptom burden, and available clinical trials, while balancing the need for both systemic disease control and CNS -specific approaches.

Insights From DESTINY-Breast12 Evaluating T-DXd in HER2+ Breast Cancer and Active and Stable Brain Metastases

February 19th 2025

Panelists discuss how the DESTINY-Breast12 trial evaluated trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer (mBC) with brain metastases, demonstrating encouraging intracranial responses and overall survival outcomes while maintaining a manageable safety profile consistent with previous T-DXd studies.

The Heart of the Matter: Unraveling the Link Between CVD and Breast Cancer for American Heart Month

February 18th 2025

Amy M. Ahnert, MD, highlights newer shared risk factors for CVD and breast cancer and questions regarding personalized screening for the diseases.

Exploring Data of PI3K/AKT/mTOR Inhibitors in HER2– mBC

February 18th 2025

Panelists discuss the use of alpelisib in light of the inavolisib approval and the impact of capivasertib (CAPItello-291 trial) on the treatment landscape and sequencing options for HR+/HER2– metastatic breast cancer (mBC).

Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer

February 18th 2025

Panelists discuss genotype-directed treatment options for advanced HR+/HER2– disease, including PI3K/AKT/mTOR inhibitors and antibody-drug conjugates (ADCs), their use based on recent data, impressions of these regimens, and how the recent first-line approval of inavolisib in combination with palbociclib and fulvestrant for PI3K-mutated HR+/HER2– metastatic breast cancer may change the treatment paradigm.

A Cardiologist Highlights the Interwoven Elements of CVD and Breast Cancer

February 17th 2025

Amy M. Ahnert, MD, details the significance of findings on the link between CVD and breast cancer as well as next steps to further define the connection.

Key Takeaways and Future Perspectives for In-House Biomarker Testing

February 17th 2025

Panelists discuss how in this discussion the top 3 key points were patient-centric care, enhanced multidisciplinary coordination, and increased access and equity. In the next 3 to 5 years there will be more decentralized testing, potentially more practices participating in genomic profiling, the cost of testing will go down and the turnaround time will be shorter.

Withdrawn Agents, Label Updates, and New Drug Formulations Shaped the Oncology Field in 2024

February 14th 2025

See this full list of regulatory decisions from 2024 regarding withdrawn agents, label updates, and new drug formulations.